PBMC Collection Services

Reduce variability risk in your PBMC studies - before it reaches the bench.

Request a Quote

All products Every PBMC product by condition, including pre-order and custom collections. In stock Lot-level PBMC inventory ready to ship in 2–3 business days, with clinical data on every sample.

All filters

Condition

Condition

Condition

Start typing to see matching condition.

Most stocked

Format

Format

Format
Sample Attributes

Sample Attributes

Volume
Additive Type
Donor Demographics

Donor Demographics

Gender
Age
Race

Start typing to see matching race.

Country
Medical History

Medical History

Medications

Start typing to see matching medications.

Comorbidities

Primary diagnosis is EHR-verified. Comorbidities are donor-reported; EHR-verified comorbidity data is available on request.

Start typing to see matching comorbidities.

Allergy List

Start typing to see matching allergy list.

Lab Results, HLA, & Testing

Lab Results, HLA, & Testing

HLA Typing
HLA-A
HLA-B
HLA-C
HLA-DRB1
HLA-DRB4
HLA-DQA1
HLA-DQB1
HLA-DPA1
HLA-DPB1
ABO Type
Rh Type
CMV Status
HIV/HBV/HCV Tested
Syphilis Tested
Flow Data

Flow Data

Has Flow Data
Viable CD45+ (% of singlets)
CD3+ T cells (% of viable CD45+)
CD4+CD8− (% of viable CD45+)
CD4−CD8+ (% of viable CD45+)
CD3−CD16/56+ NK (% of viable CD45+)
CD19+ B cells (% of viable CD45+)
CD14+ monocytes (% of viable CD45+)
Lifestyle

Lifestyle

Tobacco Use
Alcohol Use
Recreational Drug Use
Caffeine Use
Find by ID

Find by ID

Lot (SO) #

Start typing to see matching Lot (SO) #.

SKU

Start typing to see matching SKUs.

Donor ID (PID)

Start typing to see matching Donor ID (PID).

1,997 lots match
1,997 lots available Save search Notify me
Primary diagnosis is EHR-verified. Comorbidities are donor-reported; EHR-verified comorbidity data is available on request. Sample TypeBag SizeCells / VolumeAdditive TypePrimary DiseaseDiagnosisAllergiesAllergy ListHas Food AllergiesBMICMV StatusHIV/HBV/HCV TestedSyphilis TestedTobacco UseYears of SmokingPacks per DayAlcohol UseRecreational Drug UseCaffeine UseABO TypeRh TypeViable CD45+ (% of singlets)CD3+ T cells (% of viable CD45+)CD4+CD8− (% of viable CD45+)CD4−CD8+ (% of viable CD45+)CD3−CD16/56+ NK (% of viable CD45+)CD19+ B cells (% of viable CD45+)CD14+ monocytes (% of viable CD45+)Sample StatusAvailability
Healthy PBMC 58417 139255 Male 31-45 Caucasian Cryopreserved 1 mL 48 100M Bupropion XL 300mg qd. Takes Men's multivitamin — United States 2026 02:01:01:01/02:05:01:01 — — — — — — — — PBMC100M cellsACDNormal (Healthy)HealthyNo22.31Non ReactiveYesNoNoYesNOYesORH+StoredIn Stock
$578 / vial 48 vials left
Healthy PBMC 82647 23470 Female 61+ Caucasian Cryopreserved 1 mL 5 10M lisinopril 20mg QD Restasis 1 drop into both eyes BID Lexapro 20mg QD — United States 2026 02:01:01G/03:01:01G 07:02:01G/57:01:01G 06:02:01G/07:02:01G 04:07:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:01:01G/03:03:02G 01:03:01G 04:01:01G PBMC10M cellsEDTANormal (Healthy)HealthyNo23.57Non ReactiveYesNoNoNoNOYesARH+StoredIn Stock
$205 / vial 5 vials left
Myasthenia Gravis PBMC 82582 110012 Female 31-45 Caucasian Cryopreserved 1 mL 6 10M **IV bard power port needle 3/4ths** Vvygart Infusion, weekly on Mondays x4 revaluating Tylenol (with IVIG and Soliris) Benadryl (with IVIG) IV Benadryl (with Soliris) *Amitriptyline 10 mg: 4 at night *Calcium 600 mg plus D3 20 mcg: 1 in morning *Folic acid: 1mg tablets *B12 1000 mcg: 1 in morning -Continuous Meds- *Testosterone CYP 120 mg/ .6 ml subcutaneous: once every Wednesday *Lamictal 200 mg ER: 1 in morning, 1 at night *Ritalin 20 mg: 1 pill morning, 1 pill noon *buspar 10 mg: 1 pill morning, 1 pill noon, 1 pill at night *Lexapro 20 mg: 1 in morning *Seroquel 100 mg er: 3 at night -As Needed Meds- *Lorazepam 1 mg: as needed *Hydroxyzine: as needed Amlodipine tab 10mg: 1 in morning *Topamax 50 mg: 1 in morning, 1 at night *Ropinirole HCL 3 mg: 1 at night *BIPAP: Pressure 18 over 13 *Famotidine 20 mg: 1 in morning, 1 at night --As Needed Meds-- *Ondansetron ODT 4 mg: as needed *Finacea (azealic acid) *Ventolin HFA 90 mcg per actuation: as needed *Trimodal 50mg: as needed *Triamcinolone Acetonide ointment USP, 0.1%: as needed Rosacea, Hidradenitis Suppurativa, Myasthenia Gravis United States 2026 — — — — — — — — — PBMC10M cellsEDTAMyasthenia GravisMyasthenia Gravis;Rosacea;Hidradenitis SuppurativaYesbactrim, monoset, nasonex37.93NoNoNoNoNONoStoredIn Stock
$765 / vial 6 vials left
Myasthenia Gravis PBMC 73627 110012 Female 31-45 Caucasian Cryopreserved 1 mL 6 10M **IV bard power port needle 3/4ths** Vvygart Infusion, weekly on Mondays x4 revaluating Tylenol (with IVIG and Soliris) Benadryl (with IVIG) IV Benadryl (with Soliris) *Amitriptyline 10 mg: 4 at night *Calcium 600 mg plus D3 20 mcg: 1 in morning *Folic acid: 1mg tablets *B12 1000 mcg: 1 in morning -Continuous Meds- *Testosterone CYP 120 mg/ .6 ml subcutaneous: once every Wednesday *Lamictal 200 mg ER: 1 in morning, 1 at night *Ritalin 20 mg: 1 pill morning, 1 pill noon *buspar 10 mg: 1 pill morning, 1 pill noon, 1 pill at night *Lexapro 20 mg: 1 in morning *Seroquel 100 mg er: 3 at night -As Needed Meds- *Lorazepam 1 mg: as needed *Hydroxyzine: as needed Amlodipine tab 10mg: 1 in morning *Topamax 50 mg: 1 in morning, 1 at night *Ropinirole HCL 3 mg: 1 at night *BIPAP: Pressure 18 over 13 *Famotidine 20 mg: 1 in morning, 1 at night --As Needed Meds-- *Ondansetron ODT 4 mg: as needed *Finacea (azealic acid) *Ventolin HFA 90 mcg per actuation: as needed *Trimodal 50mg: as needed *Triamcinolone Acetonide ointment USP, 0.1%: as needed Myasthenia Gravis United States 2026 — — — — — — — — — PBMC10M cellsEDTAMyasthenia GravisMyasthenia GravisYesbactrim, monoset, nasonex37.93NoNoNoNoNONoStoredIn Stock
$765 / vial 6 vials left
Myasthenia Gravis PBMC 77426 110012 Female 31-45 Caucasian Cryopreserved 1 mL 4 10M **IV bard power port needle 3/4ths** Vvygart Infusion, weekly on Mondays x4 revaluating Tylenol (with IVIG and Soliris) Benadryl (with IVIG) IV Benadryl (with Soliris) *Amitriptyline 10 mg: 4 at night *Calcium 600 mg plus D3 20 mcg: 1 in morning *Folic acid: 1mg tablets *B12 1000 mcg: 1 in morning -Continuous Meds- *Testosterone CYP 120 mg/ .6 ml subcutaneous: once every Wednesday *Lamictal 200 mg ER: 1 in morning, 1 at night *Ritalin 20 mg: 1 pill morning, 1 pill noon *buspar 10 mg: 1 pill morning, 1 pill noon, 1 pill at night *Lexapro 20 mg: 1 in morning *Seroquel 100 mg er: 3 at night -As Needed Meds- *Lorazepam 1 mg: as needed *Hydroxyzine: as needed Amlodipine tab 10mg: 1 in morning *Topamax 50 mg: 1 in morning, 1 at night *Ropinirole HCL 3 mg: 1 at night *BIPAP: Pressure 18 over 13 *Famotidine 20 mg: 1 in morning, 1 at night --As Needed Meds-- *Ondansetron ODT 4 mg: as needed *Finacea (azealic acid) *Ventolin HFA 90 mcg per actuation: as needed *Trimodal 50mg: as needed *Triamcinolone Acetonide ointment USP, 0.1%: as needed Hidradenitis Suppurativa, Myasthenia Gravis United States 2026 — — — — — — — — — PBMC10M cellsEDTAMyasthenia GravisMyasthenia Gravis;Hidradenitis SuppurativaYesbactrim, monoset, nasonex37.93NoNoNoNoNONoStoredIn Stock
$765 / vial 4 vials left
Osteoarthritis PBMC 82711 154650 Female 46-60 African American Cryopreserved 1 mL 5 10M amLODIPine (NORVASC) 10 MG 1xday ghydroCHLOROthiazide 12.5 MG 1xday atorvastatin (LIPITOR) 20 MG 1xday Carvedilol 12.5 MG 1xday Osteoarthritis United States 2026 — — — — — — — — — PBMC10M cellsEDTAOsteoarthritisOsteoarthritisNo42.43NoNoUsed to Smoke100.5NoNOYesStoredIn Stock
$530 / vial 5 vials left
Diabetes Type II PBMC 82618 123905 Male 61+ Caucasian Cryopreserved 1 mL 27 50M Balsalazide 750mg 3x TID Nitroglycerine Ointment 1.5mg/inch of ointment BID Stelara IV infusion Q8W (last ) Metformin 1000mg BID Glipizide 10mg BID Tamsulosin QD Finasteride QD FARXIGA® (dapagliflozin)/QD Ulcerative Colitis, Crohn's Disease, Diabetes Type II United States 2026 03:01:01G/31:01:02G 35:02:01G/37:01:01G 04:01:01G/06:02:01G 04:03:01G/11:04:01G 01:01:01G 03:01:01G/05:01:01G 03:01:01G/03:05:01G 01:03:01G 04:01:01G/04:02:01G PBMC50M cellsACDDiabetes Type IIDiabetes Type 2;Ulcerative Colitis;Crohn's DiseaseYesAmoxicillin27.8Non ReactiveYesYesNoNoNOYesORH+StoredIn Stock
$1,109 / vial 27 vials left
Diabetes Type II PBMC 82618 123905 Male 61+ Caucasian Cryopreserved 1 mL 12 10M Balsalazide 750mg 3x TID Nitroglycerine Ointment 1.5mg/inch of ointment BID Stelara IV infusion Q8W (last ) Metformin 1000mg BID Glipizide 10mg BID Tamsulosin QD Finasteride QD FARXIGA® (dapagliflozin)/QD Ulcerative Colitis, Crohn's Disease, Diabetes Type II United States 2026 03:01:01G/31:01:02G 35:02:01G/37:01:01G 04:01:01G/06:02:01G 04:03:01G/11:04:01G 01:01:01G 03:01:01G/05:01:01G 03:01:01G/03:05:01G 01:03:01G 04:01:01G/04:02:01G PBMC10M cellsACDDiabetes Type IIDiabetes Type 2;Ulcerative Colitis;Crohn's DiseaseYesAmoxicillin27.8Non ReactiveYesYesNoNoNOYesORH+StoredIn Stock
$530 / vial 12 vials left
Rheumatoid Arthritis PBMC 80885 1557857 Female 61+ Hispanic/Latino Cryopreserved 1 mL 2 5M CTLA-1 Ig therapy (abatacept) Rheumatoid Arthritis — 2026 — — — — — — — — — PBMC5M cellsNAHEPRheumatoid ArthritisRheumatoid ArthritisNo31.61NoNoNoNoNONoStoredIn Stock
$530 / vial 2 vials left
Breast Cancer PBMC 82455 157878 Female 46-60 Caucasian Cryopreserved 1 mL 59 50M EMGALITY – MIGRAINE PROPHYLAXIS 70 MG MONTHLY Breast Cancer United States 2026 01:01:01G/26:01:01G 08:01:01G/35:01:01G 04:01:01G/07:01:01G 03:01:01G/04:02:01G 01:01:01G 03:01:01G/05:01:01G 02:01:01G/03:02:01G 01:03:01G/02:01:02G 01:01:01G/04:01:01G PBMC50M cellsACDBreast CancerBreast CancerNo23.29Non ReactiveNoYesNoYesNOYesStoredIn Stock
$1,195 / vial 59 vials left
Breast Cancer PBMC 82455 157878 Female 46-60 Caucasian Cryopreserved 1 mL 9 10M EMGALITY – MIGRAINE PROPHYLAXIS 70 MG MONTHLY Breast Cancer United States 2026 01:01:01G/26:01:01G 08:01:01G/35:01:01G 04:01:01G/07:01:01G 03:01:01G/04:02:01G 01:01:01G 03:01:01G/05:01:01G 02:01:01G/03:02:01G 01:03:01G/02:01:02G 01:01:01G/04:01:01G PBMC10M cellsACDBreast CancerBreast CancerNo23.29Non ReactiveNoYesNoYesNOYesStoredIn Stock
$1,195 / vial 9 vials left
Atopic Dermatitis (Eczema) PBMC 82520 138119 Female 31-45 Hispanic/Latino Cryopreserved 1 mL 10 10M — Atopic Dermatitis (Eczema) United States 2026 A*01:01:01G/A*29:02:01G B*44:03:01G/B*52:01:01G C*04:01:01G/C*12:02:01G — — — — — — PBMC10M cellsEDTAAtopic Dermatitis (Eczema)Atopic DermatitisNo36.02ReactiveYesNoNoNoNONoStoredIn Stock
$530 / vial 10 vials left
Healthy PBMC 82308 156355 Male 18-30 Caucasian Hispanic/Latino Asian/Pacific Islander Cryopreserved 1 mL 49 100M — — United States 2026 02:01:01G/24:02:01G 44:02:01G 05:01:01G 04:02:01G/13:01:01G 01:01:01G 01:03:01G/03:01:01G 03:02:01G/06:03:01G 01:03:01G/02:01:01G 04:01:01G/10:01:01G PBMC100M cellsACDNormal (Healthy)HealthyNo32.98Non ReactiveYesNoNoNoNOYesBRH+StoredIn Stock
$578 / vial 49 vials left
Healthy PBMC 82308 156355 Male 18-30 Caucasian Hispanic/Latino Asian/Pacific Islander Cryopreserved 1 mL 12 25M — — United States 2026 02:01:01G/24:02:01G 44:02:01G 05:01:01G 04:02:01G/13:01:01G 01:01:01G 01:03:01G/03:01:01G 03:02:01G/06:03:01G 01:03:01G/02:01:01G 04:01:01G/10:01:01G PBMC25M cellsACDNormal (Healthy)HealthyNo32.98Non ReactiveYesNoNoNoNOYesBRH+StoredIn Stock
$248 / vial 12 vials left
Behcet's Disease PBMC 82314 157568 Male 18-30 African American Other Cryopreserved 1 mL 3 10M — Behcet's Disease United States 2026 — — — — — — — — — PBMC10M cellsEDTABehcet's DiseaseBehcet's DiseaseYesTramadol, Doxycycline Hyclate26.87NoNoNo00NoNOYesStoredIn Stock
$891 / vial 3 vials left
Rheumatoid Arthritis PBMC 82144 25855 Female 31-45 Hispanic/Latino Cryopreserved 1 mL 140 50M Methotrexate 9 tablets q week, Wellbutrin 150mg daily, Hydroxychloroquine 200mg BID, Amjevita 40 mg q 2 weeks Rheumatoid Arthritis United States 2026 — — — — — — — — — PBMC50M cellsACDRheumatoid ArthritisRheumatoid ArthritisNo39.48Non ReactiveYesYesNoYesNOYesORH+StoredIn Stock
$1,109 / vial 140 vials left
Rheumatoid Arthritis PBMC 82144 25855 Female 31-45 Hispanic/Latino Cryopreserved 1 mL 12 10M Methotrexate 9 tablets q week, Wellbutrin 150mg daily, Hydroxychloroquine 200mg BID, Amjevita 40 mg q 2 weeks Rheumatoid Arthritis United States 2026 — — — — — — — — — PBMC10M cellsACDRheumatoid ArthritisRheumatoid ArthritisNo39.48Non ReactiveYesYesNoYesNOYesORH+StoredIn Stock
$530 / vial 12 vials left
Healthy PBMC 58333 23470 Female 61+ Caucasian Cryopreserved 1 mL 73 100M lisinopril 20mg QD Restasis 1 drop into both eyes BID Lexapro 20mg QD — United States 2026 02:01:01G/03:01:01G 07:02:01G/57:01:01G 06:02:01G/07:02:01G 04:07:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:01:01G/03:03:02G 01:03:01G 04:01:01G PBMC100M cellsACDNormal (Healthy)HealthyNo23.57Non ReactiveYesNoNoNoNOYesARH+StoredIn Stock
$578 / vial 73 vials left
Healthy PBMC 58333 23470 Female 61+ Caucasian Cryopreserved 1 mL 1 25M lisinopril 20mg QD Restasis 1 drop into both eyes BID Lexapro 20mg QD — United States 2026 02:01:01G/03:01:01G 07:02:01G/57:01:01G 06:02:01G/07:02:01G 04:07:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:01:01G/03:03:02G 01:03:01G 04:01:01G PBMC25M cellsACDNormal (Healthy)HealthyNo23.57Non ReactiveYesNoNoNoNOYesARH+StoredIn Stock
$248 / vial 1 vial left
Healthy PBMC 65809 23470 Female 61+ Caucasian Cryopreserved 1 mL 11 100M lisinopril 20mg QD Restasis 1 drop into both eyes BID Lexapro 20mg QD — United States 2026 02:01:01G/03:01:01G 07:02:01G/57:01:01G 06:02:01G/07:02:01G 04:07:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:01:01G/03:03:02G 01:03:01G 04:01:01G PBMC100M cellsACDNormal (Healthy)HealthyNo23.57Non ReactiveYesNoNoNoNOYesARH+StoredIn Stock
$578 / vial 11 vials left
Healthy PBMC 82552 153892 Male 31-45 Hispanic/Latino Cryopreserved 1 mL 30 100M No medications — United States 2026 A*24:02:01:01/A*31:01:02:01 — — — — — — — — PBMC100M cellsACDNormal (Healthy)HealthyNo19.76ReactiveYesNoNoNoNONoORH+StoredIn Stock
$578 / vial 30 vials left
Healthy PBMC 82552 153892 Male 31-45 Hispanic/Latino Cryopreserved 1 mL 12 25M No medications — United States 2026 A*24:02:01:01/A*31:01:02:01 — — — — — — — — PBMC25M cellsACDNormal (Healthy)HealthyNo19.76ReactiveYesNoNoNoNONoORH+StoredIn Stock
$248 / vial 12 vials left
Systemic Lupus Erythematosus (SLE) PBMC 82005 106846 Female 46-60 Caucasian Cryopreserved 1 mL 6 10M Levothyroxine Urso Iqirvo Tymlos Atorvastatin Vit d Senna Pepcid Clobetosol Rifampin Ursodiol 1250mg total Ocaliva 10mg po qd Atorvastatin 40mg po qd Levothyroxine 150mcg po qd Pantoprozole 40mg po qd Rifampin 150mg po bid Calcium citrate 1200mg po qd Primary Biliary Cholangitis (Cirrhosis), Systemic Lupus Erythematosus (SLE) United States 2026 01:01:01G/24:02:01G 35:03:01G/37:01:01G 06:02:01G/12:03:01G 04:01:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:02:01G/03:03:02G 01:03:01G 04:01:01G PBMC10M cellsEDTASystemic Lupus Erythematosus (SLE)Lupus (SLE);Primary Biliary CholangitisNo34.67NoNoUsed to Smoke1010NoNOYesStoredIn Stock
$530 / vial 6 vials left
Heart Failure PBMC 81903 154842 Male 61+ Caucasian Cryopreserved 1 mL 8 10M advil 1 200mg PRN asprin 81mg 1xday astrovostatin 20mg 1xday beet root 2 1500mg daily calcium 600 vit d 20 1 xday alviterol 25mg 2xday cinnamon 25mg daily aquiibrol 75mg daily viscovy 200 25mg 1x day duloxitine 60mg day fish oil 1000mg daily flonase 50mcg prn permosimide 20mg daily hydroxine 150mg prn iron 325mg daily mag oxide 420mg daily orpatnadeane cirtrate 100mg prn pentabizole 40mg prn potassium choloride 10meq daily generic celaas trazadone 50mg prn trilicity 450mg weekly tumeric 2000mg daily vit b12 300mg daily zenpep prn occ.- thc gummies Heart Failure United States 2026 — — — — — — — — — PBMC10M cellsEDTAHeart FailureHeart FailureNo25.52NoNoUsed to Smoke292YesYESYesStoredIn Stock
$765 / vial 8 vials left
Primary Biliary Cholangitis (Cirrhosis) PBMC 73540 106846 Female 46-60 Caucasian Cryopreserved 1 mL 2 10M Levothyroxine Urso Iqirvo Tymlos Atorvastatin Vit d Senna Pepcid Clobetosol Rifampin Ursodiol 1250mg total Ocaliva 10mg po qd Atorvastatin 40mg po qd Levothyroxine 150mcg po qd Pantoprozole 40mg po qd Rifampin 150mg po bid Calcium citrate 1200mg po qd Primary Biliary Cholangitis (Cirrhosis) United States 2026 01:01:01G/24:02:01G 35:03:01G/37:01:01G 06:02:01G/12:03:01G 04:01:01G/07:01:01G 01:01:01G 02:01:01G/03:01:01G 03:02:01G/03:03:02G 01:03:01G 04:01:01G PBMC10M cellsEDTAPrimary Biliary Cholangitis (Cirrhosis)Primary Biliary CholangitisNo34.67NoNoUsed to Smoke1010NoNOYesStoredIn Stock
$891 / vial 2 vials left

Adding a lot to your cart does not reserve it. Lots are confirmed when the order is placed.

Vial counts can change between daily syncs; a ✓ shows when a lot's count was last checked, not a hold.

Showing 1–25 of 1,997 lots* Primary diagnosis is EHR-verified. Comorbidities are donor-reported; EHR-verified comorbidity data is available on request.

Custom Biospecimen Sourcing

Custom PBMC Collection Services for Clinical Studies

Donor variability is the most common, and most expensive failure mode in PBMC-dependent research. A cohort that doesn't match your protocol on disease state, treatment history, or demographics doesn't just slow down a study; it compromises the data you're using to make go/no-go decisions on therapeutic candidates.

Sanguine builds custom PBMC cohorts to your exact specifications, sourced from a network of verified-condition donors and delivered with the integrated clinical and demographic data your team needs to interpret results with confidence. Whether you're running an immuno-oncology screen or building a rare-disease biomarker panel, we tailor the donor profile, collection method, and processing pipeline to your protocol - not the other way around.

Talk to a sourcing specialist →

Explore Ready-to-Ship PBMCs →

Network at a glance

Built for protocol-specific sourcing

70K+
Consented donors
150+
Verified conditions
5M–2B
Cells per donor
4–16wk
Typical delivery

EHR-verified donor conditions

In-home + clinic-based collection

Longitudinal donor recall

What makes a "custom" PBMC cohort?

A custom PBMC cohort is one where every donor and every aliquot is sourced and processed against criteria you define, rather than pulled from off-the-shelf inventory. At Sanguine, that typically means specifying:

Disease state and severity

Verified through medical records review, not donor self-report.

Treatment status

Treatment-naïve, on a specific therapy, post-treatment, or in remission.

Demographics

Age range, sex, race/ethnicity, BMI, comorbidities.

Biomarker profile

HLA type, mutation status, expression markers, serology.

Collection parameters

Volume, anticoagulant, processing time-to-freeze, viability thresholds.

Longitudinal cadence

Single timepoint, paired samples, or repeat draws over months.

The result is a cohort that minimizes variability and maximizes the signal your assay is designed to detect.

Donor Network

How Sanguine sources verified-condition donors

Most PBMC suppliers rely on commercial blood centers, where donor selection is limited to whatever walks through the door. We built Sanguine differently.

Our donor network is composed of individuals who have signed up specifically to contribute biospecimens to research, and who have consented to share medical record data. That structure gives us three advantages that translate directly into better PBMCs for your study:

Condition verification through medical records

When a donor reports a diagnosis, we confirm it against their EHR before they're eligible for a study. This means that a "treatment-naïve metastatic NSCLC" cohort actually contains individuals who meet that definition.

In-home and clinic-based collection

The majority of our collections happen in the donor's home, which dramatically widens the geographic pool and lets us recruit people who would never travel to a fixed collection site. For rare diseases, this is often the only way to assemble a cohort at all.

Longitudinal access

Because donors are part of an ongoing network, we can return to the same individuals for paired baseline/on-treatment samples or extended follow-up without rebuilding consent each time.

Our network includes over 70,000 consented individuals with verified coverage of 150+ conditions.

What you can customize

SpecificationOptions
Donor profileDisease state, treatment history, biomarker status, demographics, HLA type
Sample typeFresh PBMCs, cryopreserved PBMCs, paired plasma/serum, whole blood
Cells per donor5M to 2B cells/donor
ProcessingDensity gradient, custom isolation protocols
CryopreservationDMSO/serum, DMSO-free, controlled-rate freezing, vapor-phase storage

Integrated Data

Integrated donor data - included, not extra

Every PBMC sample we deliver ships with structured donor metadata so your team isn't reverse-engineering context from a vial label.

For studies that need it, we also support deeper EHR pulls, longitudinal patient-reported outcomes, and integration with your LIMS or analysis platform.

Standard data package

  • Demographics and consent status
  • Verified diagnosis
  • Current and historical medications
  • Relevant lab values from the donor's medical record
  • Collection-day questionnaire responses
  • Sample handling chain-of-custody (collection-to-freeze time, processing site, lot)

Use cases

PBMC collections for oncology trials

For immuno-oncology programs, the value of a PBMC cohort lives in the specificity of the donor selection. We routinely build cohorts for:

  • Solid-tumor indications stratified by stage, mutation status, and prior therapy
  • Treatment-naïve baseline cohorts paired with on-treatment timepoints
  • CAR-T and TIL development programs requiring high-volume leukopaks from healthy or patient donors
  • Biomarker discovery panels with matched tumor and peripheral samples
  • Pharmacodynamic studies requiring serial bleeds over weeks or months

Because we verify diagnosis and treatment status against medical records, your "post-checkpoint-inhibitor" cohort isn't contaminated by patients whose treatment history was misremembered or self-reported in error.

PBMC collections for rare disease research

Rare-disease cohorts are the hardest to assemble - and the area where most off-the-shelf vendors simply can't help. Sanguine's patient-recruited network and in-home collection model make us a natural fit when your protocol calls for:

  • Ultra-rare indications with prevalence below 1 in 50,000
  • Geographically distributed collection across multiple states
  • Patients on highly specific genetic, autoimmune, or metabolic-disease registries
  • Family/proband studies requiring relative-paired samples

Read how Sanguine partnered with GEM for a longitudinal first-degree relative study → (opens in new tab)

Vendor Evaluation

How Sanguine compares to other PBMC suppliers

When biopharma teams evaluate PBMC sourcing partners, the criteria that actually predict study success aren't price-per-vial. Use this checklist when you're comparing vendors - including us.

CriterionWhy it mattersWhat to ask
Donor verification methodSelf-reported diagnoses introduce silent variability."How do you confirm the donor's stated condition?"
Network modelWalk-in blood centers can't deliver rare-disease or longitudinal cohorts."Are donors recruited and retained, or sourced one-time?"
Geographic reachSingle-site networks miss patients who can't travel."Can you collect at the donor's home?"
Data integrationA vial without context is a sample of unknown clinical relevance."What clinical and demographic metadata ships with each sample?"
Customization depthOff-the-shelf inventory rarely matches a real protocol."What variables can I specify, and which are fixed?"
Longitudinal accessTreatment-effect studies need the same donor across timepoints."Can you recall the same donor 3 months from now?"
Regulatory rigorConsents and CoCs must hold up to FDA/EMA scrutiny."Can you share a sample IRB protocol and donor consent?"

FAQ

Frequently asked questions

What does Sanguine's PBMC collection service include?
Custom donor recruitment against your protocol-specified criteria, blood collection (in-home or in-clinic), processing to fresh or cryopreserved PBMCs, viability and identity QC, and delivery with integrated donor metadata.
How does Sanguine reduce donor variability in PBMC collections?
By verifying donor conditions against medical records, standardizing collection-to-freeze timing across collection sites, applying consistent processing protocols, and shipping each sample with the clinical metadata needed to model variability rather than guess at it.
Can Sanguine collect PBMCs from rare-disease patients?
Yes. Our donor-recruited network and in-home collection capability make us particularly well-suited to rare-disease cohorts that conventional commercial blood centers can't assemble.
What's a typical timeline for a custom PBMC cohort?
Typical timelines, e.g., 4–6 weeks for common indications, 8–16 weeks for rare cohorts, with a feasibility assessment in the first week.
Can I get paired baseline and on-treatment PBMC samples from the same donor?
Yes. Because our donors are part of an ongoing recruited network, longitudinal collection is a standard offering. We routinely support 2–6 timepoint protocols and can build longer cadences when the science requires it.
How do I share study specifications with Sanguine?
Most engagements start with a 30-minute scoping call. We translate your protocol into recruitment criteria, return a feasibility estimate (donor availability, timeline, cost), and finalize a Statement of Work before any collections begin.

Get Started

Ready to design your cohort?

Tell us what your protocol needs. We'll come back with a feasibility assessment, including donor availability, timeline, and pricing.